Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Trial details
- Registry ID
- NCT06973629
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as NurOwn
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)NCT06973629 | Brainstorm-Cell Therapeutics | Phase 3 | Not yet recruiting | 2028-11-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |